## Remarks

Claims 1 to 37 were pending. By this Amendment, claims 1 to 37 were amended. No new matter has been added thereby. Accordingly, entry of the Amendment is respectfully requested. Claims 1 to 37, as amended, are now pending.

The Examiner rejected claims 1 to 37 under 35 U.S.C. § 112, first and second paragraphs, for various alleged specified reasons in the office action.

In response, applicants have amended the claims and maintain that such amendments generally render the Examiner's rejections moot. Applicants traverse some rejections, however, as follows. With regard to as to claim 32, applicants maintain that such recitation is sufficiently clear, but would be willing to designate the two inhalers by a term, such as "the Weston *et al.* nebulizer" and "the RESPIMAT nebulizer" instead. With regard to claim 35, applicants point out that the terms treating or preventing need not involve a cure of such conditions, but merely show a reasobale reasonable likelihood of allevatingalleviating some condition associated with inflammatory or respiratory diesaeses diseases, which is likely given the biological activity of the compounds.

The Examiner also requested thjethe structures of the compounds listed in claim 4.

In response, applicants herewith provide the following structures.

Compound No.	Structure
YM-35375	

BIIF 1149	
	Ph 0 Me CH2—N—CH—C—N—CH2—CH2—CF3
MEN-11467	HN Me Me
MEN-11149	O Me Me
MEN-10930	Ph N Me N N N N N N N N N N N N N N N N N
MEN-11420	PAGE  ORS  RRR  NHA  NHA  I-BU

Page 14 of 21

CJ-11974	S CHPh2  Pr-i
TAK-637	F3C Ne
SR 144190	Me2N Ph
MDL-103896	MeO OME OME OME OME OME

T 1051 - 1051 - 1	
MDL-105172A	MeO MeO HC1
S 19752	(CH2)4 OH NH CF3 CF3
DA-5018	Me Me (CH2)3-NH-C-CH2 ● HC1
SB 223412	OH Ph

YM-44778	PAGE 1-	Α
	OME OME OME OME CH2 CH2 CH2 CH2 CH2 CH2	
	PAGE 2-A	Δ,
YM-49244	i-Pro CH2—CH2 CH2 CH2 CH2 N+ Me NH NH	
L 758298	H2O3P N S R O R CF3	

Page 17 of 21

L 754030 = MK 869	HN N S R CF3
LY 303870	N AC OME
GR 205171	OME Ph
GR 205171A	OME Ph S NH CF3
SR 48968	Ph NHAC C1

Page 18 of 21

SR 140333	
SK 140333	
	OPr-i
	0
	C1
:	( ) c1
	Ph
	Pu
CP 122721	ρме
	S S NH
	H ₽h
	F3C 0
	. 30
FK 888	Me .
	OH >
	S N
:	Me N Ph
DNK-333 =	
DNK333A	c1 c1
DIVICIONA	
	F 0 0
	C* N*
	F
	F

Page 19 of 21

The Examiner rejected claims 1 to 37 under the judicially-created doctrine of obviousness-type double patenting over claims 1 to 18 of Pairet *et al.*, U.S. Patent No. 6,455,524 in view of Banholzer *et al.*, USSN 10/391,735.

In response, applicants traverse the rejection and contend that it is improper. The Examiner has conceded that Pairet *et al.* does not disclose or claim the instant anticholinergics and has not explained the motivation to combine the references or why there would be a reasonable expectation of success in making such a modification to Pairet *et al.* as required for a proper *prima facie* case of obviousness. Accordingly, applicants respectfully request that the Examiner reconsider and withdraw the rejection.

Applicants submit that all the pending claims are allowable and respectfully solicit a Notice of Allowance for all of the pending claims. If the Examiner feels that a telephone interview

Serial No. 10/614,362 Reply dated November 1, 2004 Reply to Office Action dated June 3, 2004

would be helpful in advancing prosecution of this application, the Examiner is invited to contact the attorney below.

Certificate of Mailing Under 37 C.F.R. § 1.8(a) I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 1,

Timothy X. Witkowski Registration No. 40,232

Dated

2004.

Respectfully submitted,

Timothy X. Witkowski Registration No. 40,232 Attorney for Applicants

BOEHRINGER INGELHEIM CORPORATION Patent Department 900 Ridgebury Road P.O. Box 368

Ridgefield, CT 06877 Telephone: (203) 798-4310 Facsimile: (203) 798-4408